Ranked #2,143 of 8,699 institutional investors
Redmile Group, LLC
Larkspur, CA
$1.16B
US stock portfolio at live prices · today +$5.6M (+0.48%)
Market closed. Prices as of Nov 20, 8:11 AM ET
- Value at quarter end (Q3 2026)
- $1.37B
- Change from Q2 2026
- −$123.3M (−8.28%)
- Positions
- 41 · 5 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$24.3M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKRYS 14.3%SRRK 13.1%NRIX 9.24%STOK 8.96%IMNM 6.23%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | 527,684 | $167M | 14.3% | Reduced −17% |
| SRRK Scholar Rock Holding Corporation | 3,033,962 | $153M | 13.1% | Reduced −30% |
| NRIX Nurix Therapeutics, Inc. | 7,901,085 | $107M | 9.24% | Added +94% |
| STOK Stoke Therapeutics, Inc. | 3,869,028 | $104M | 8.96% | Reduced −2% |
| IMNM Immunome, Inc. | 4,363,064 | $72.5M | 6.23% | Reduced −11% |
| ABSI Absci Corporation | 6,671,377 | $54.4M | 4.68% | Reduced −1% |
| SLN Silence Therapeutics plc | 2,460,894 | $48.8M | 4.19% | Added +14% |
| ANNX Annexon, Inc. | 14,278,075 | $48.7M | 4.19% | Added +20% |
| ETRA Electra Therapeutics, Inc. | 5,430,918 | $48.6M | 4.17% | New |
| RGNX REGENXBIO Inc. | 5,048,502 | $36.2M | 3.12% | Added +16% |
| NGNE Neurogene Inc. | 1,562,199 | $35.8M | 3.08% | Added +11% |
| STTK Shattuck Labs, Inc. | 5,086,990 | $23.1M | 1.99% | Reduced −26% |
| BEAM Beam Therapeutics Inc. | 1,061,782 | $22.2M | 1.91% | Reduced −9% |
| ATTO Attovia Therapeutics, Inc. | 1,163,587 | $18.1M | 1.56% | New |
| ZYME Zymeworks Inc. | 491,654 | $13.2M | 1.14% | Unchanged |
| FATE Fate Therapeutics, Inc. | 12,872,946 | $13.0M | 1.12% | Unchanged |
| SLDB Solid Biosciences Inc. | 1,944,342 | $12.5M | 1.08% | Reduced −0% |
| BMRN BioMarin Pharmaceutical Inc. | 189,538 | $11.6M | 1.00% | Reduced −29% |
| NUVB Nuvation Bio Inc. | 3,031,009 | $11.5M | 0.99% | Unchanged |
| ADRX ADARx Pharmaceuticals, Inc. | 769,345 | $10.9M | 0.94% | New |
| AURA Aura Biosciences, Inc. | 1,552,479 | $10.8M | 0.93% | Reduced −7% |
| OBX Obsidian Therapeutics, Inc. | 833,157 | $10.1M | 0.87% | New |
| IDYA IDEAYA Biosciences, Inc. | 381,319 | $10.0M | 0.86% | Reduced −40% |
| CBLL Ceribell Inc | 386,786 | $10.0M | 0.86% | Unchanged |
| AGMB AgomAb Therapeutics NV | 1,740,230 | $9.8M | 0.84% | Reduced −36% |
| CLYM Climb Bio Inc | 974,489 | $9.0M | 0.78% | Reduced −21% |
| CLDX Celldex Therapeutics, Inc. | 321,770 | $9.0M | 0.77% | Reduced −26% |
| COGT Cogent Biosciences, Inc. | 296,606 | $8.2M | 0.71% | Reduced −41% |
| ALXO ALX Oncology Holdings Inc. | 7,185,263 | $7.3M | 0.63% | Reduced −3% |
| XENE Xenon Pharmaceuticals Inc. | 191,036 | $7.2M | 0.62% | Reduced −17% |
| ODTX Odyssey Therapeutics, Inc. | 374,510 | $6.9M | 0.59% | Reduced −12% |
| INSM Insmed Incorporated | 42,902 | $6.2M | 0.53% | Reduced −16% |
| PRME Prime Medicine, Inc. | 1,146,860 | $4.4M | 0.38% | Reduced −17% |
| ATRA Atara Biotherapeutics, Inc. | 636,852 | $4.0M | 0.35% | Added +44% |
| DBVT DBV Technologies S.A. | 373,417 | $3.5M | 0.30% | Reduced −9% |
| EPRX Eupraxia Pharmaceuticals Inc. | 519,881 | $3.2M | 0.27% | Reduced −15% |
| ORIC ORIC Pharmaceuticals, Inc. | 292,817 | $2.3M | 0.19% | Reduced −19% |
| ARDX Ardelyx, Inc. | 523,870 | $1.6M | 0.14% | Reduced −18% |
| OCUL Ocular Therapeutix, Inc. | 243,954 | $1.4M | 0.12% | New |
| IVVD Invivyd, Inc. | 2,285,320 | $1.0M | <0.1% | Reduced −12% |
| PLRX Pliant Therapeutics, Inc. | 772,126 | $479K | <0.1% | Unchanged |